Originally published by our sister publication Infectious Disease Special Edition
The FDA granted a new indication for letermovir (Prevymis, Merck) for prophylaxis of cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients.
High-risk patients are cases in which the donor was CMV-seropositive and the kidney recipient was CMV-seronegative (D+/R-).